Cure8 trial brief
A large clinical registry can help researchers learn more about IBD patterns, potential causes, and who might be eligible for future clinical trials. For patients, joining may help advance research and make it easier to be invited to studies relevant to your condition.
Adult patients with Crohn’s disease or ulcerative colitis treated at the UPMC Center for Inflammatory Bowel Disease; clinicians and researchers interested in IBD cohorts and study recruitment.
This is a recruiting observational IBD research registry at the University of Pittsburgh (UPMC) that aims to enroll up to 5,000 adults seen at the Center for Inflammatory Bowel Disease.
The registry will collect identifiable medical record information to support retrospective research, improve disease classification, study factors that influence the natural history of Crohn’s disease and ulcerative colitis, and help identify and recruit participants for future studies.
Participants provide written informed consent for placement of their IBD-related medical record data into the registry. The record says the registry’s goals include better understanding of IBD pathogenesis, enabling development of better or preventive therapies, and facilitating future research recruitment.
The study is observational, planned duration up to 20 years for the primary outcome (number of patients with IBD), and is recruiting at UPMC in Pittsburgh.
If you are considering joining, review the registry consent and privacy protections with the study team; the registry stores identifiable records and is intended to support many future studies rather than testing a specific treatment.
This is an observational registry (not a treatment trial). It collects identifiable medical-record data to support retrospective research and recruitment. Participation involves consent to store your IBD-related records; check the study team’s details about data use and privacy. The record is a trial registration (ClinicalTrials.gov); it does not report results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.
Clinical trials are how new IBD tests and treatments are developed; joining one can give access to interventions and helps improve care for people with Crohn’s disease or ulcerative colitis. The article gives practical...
